HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Tatyana Feldman(Hackensack University Medical Center), Maryam Sarraf Yazdy(Georgetown University), Bradley M. Haverkos(University of Colorado Denver), Madelyn Burkart(Atrium Health Wake Forest Baptist), Kirsten M Boughan(Cleveland Clinic), Christopher R. D’Angelo(Susan Thompson Buffett Foundation), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Catherine Diefenbach(NYU Langone Health), Paolo F. Caimi(University Hospitals Seidman Cancer Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Emma Rabinovich(University of Illinois Chicago), Adam Zayac(Rutgers, The State University of New Jersey), Vaishalee P. Kenkre(University of Wisconsin–Madison), Parameswaran Venugopal(Rush University Medical Center), Michael C. Churnetski(Emory University), Gaurav Varma(NYU Langone Health), Peter Martin(Northwestern University), Catherine Zhu(University College Hospital), Seo‐Hyun Kim(Rush University Medical Center), Allandria Straker-Edwards(Fox Chase Cancer Center), David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Amandeep Godara(University of Utah), Kristie A. Blum(Emory University), Adam J. Olszewski(Memorial Hospital of Rhode Island), Catherine Wei(Rutgers, The State University of New Jersey), Andreas K. Klein(Tufts Medical Center), Mark Bower(Chelsea and Westminster Hospital), Andrew M. Evens(Rutgers, The State University of New Jersey), Frank A. Post(King's College Hospital NHS Foundation Trust), Alexey V. Danilov(City of Hope), Amy Sperling(Fred Hutch Cancer Center), Victor M. Orellana‐Noia(University of Virginia), Stephanie Berg(Loyola University Medical Center), Nadia Khan(Fox Chase Cancer Center), Seth Maliske(University of Iowa), Agrima Mian(Cleveland Clinic), Shireen Kassam, Nishitha Reddy(Vanderbilt University), Ayushi Chauhan(Georgetown University), Narendranath Epperla(University of Utah), Umar Farooq(Wake Forest University), Graham P. Collins(Churchill Hospital), Alessia Dalla Pria(Chelsea and Westminster Hospital), Scott E. Smith(Loyola University Medical Center), Albert Ren, Ryan Vaca(Penn State Milton S. Hershey Medical Center), Reem Karmali(Northwestern University), Yun Kyong Choi(New York University), Manali Kamdar(University of Colorado Cancer Center)
Cited by 54
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k